ArticleCureus2025
Transvaginal and Transurethral High-Dose-Rate Brachytherapy in a Patient With Malignant Vaginal Melanoma and Urethral Invasion: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 60-year-old woman presented with abnormal genital bleeding. Colposcopy and cystoscopy revealed black pigmented lesions in the vulva, vaginal vestibule, vaginal fornix, external urethral orifice, and urethral mucosa. The patient was diagnosed with vaginal malignant melanoma and urethral invasion. Because the melanoma was confined to the vagina and urethra, high-dose-rate brachytherapy using Ir-192 was selected. Vaginal lesions were irradiated using a vaginal applicator and the urethral lesions were irradiated by inserting a flexible catheter into the urethral catheter. The total radiation dose was 48 Gy in eight fractions. Pembrolizumab was started one month after radiotherapy. All black pigmented lesions disappeared within six months after brachytherapy. There was no sign of recurrence at 15 months after treatment. Adverse events included Grade 2 perivaginal inflammation at 6 weeks after treatment and Grade 3 vaginal stenosis at 15 months after treatment. The combination of intracavitary irradiation using a vaginal applicator and transurethral irradiation using a flexible catheter within a urethral catheter enabled delivery of an adequate tumor dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.